Sjogren's Trials
The Division of Rheumatology strives to understand more about Sjogren's through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact
|
Efgartigimod- ARGENX
IRB # 25-0435 Elena Weinstein, MD | Phase 3 evaluation of the efficacy of Efgartigimod for the treatment of moderate to severe Primary Sjogren’s Joint Disease. | Eligibility: -Age 18 or older -Diagnosis of Primary Sjogren’s with active disease. - SSA antibody positive - No use of cannabis/cannabinol within 12 months of screening. | Chong Pedrick 303-724-8948 Najeeb Arishi 303-724-8948 |